Drug maker Pfizer Inc. could part with or distance itself from some of its research programs as it rethinks its approach to early development research in rare diseases and cancer treatments, the company said Thursday.
The move by Pfizer PFE would mark a considerable shift for a company trying to carve a path forward as demand for COVID-19 drugs fades and as patents expire in the years ahead, according to Barron’s, which reported the remarks earlier in the day. Barron’s reported that the company said that selling some assets was also an option. According to Barron’s, the segments that Pfizer is targeting for so-called “externalization” were in early stage rare-disease programs focused on cardiology, neurology and gene-therapy programs that weren’t yet under trial. Pfizer is also weighing such options for its gene-therapy manufacturing plant in Durham, N.C., that opened in late 2021, Barron’s said.
Pfizer’s moves won’t affect rare-disease medications whose development are in the later stages, Barron’s said. The biopharma industry over recent years has leaned in to developing treatments for rare diseases, Barron’s noted, but added that critics have argued that the focus on treating rare diseases has come at the expense of those that aren’t as rare.
Government backed criminals
Pfizer will go to zero when it’s all said and done.
Let’s all make ourselves as healthy as possible to avoid this corrupt, immoral, unethical company’s products at all costs unless absolutely necessary.